

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95272

Kazuhito IKEDA, et al.

Appln. No.: 10/581,663

Group Art Unit: 1614

Confirmation No.: 4563

Examiner: Not Yet Assigned

Filed: June 5, 2006

For: THERAPEUTIC OR PREVENTIVE AGENTS FOR ISCHEMIC NEUROPATHY

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. WO 03/062243 A, published July 30, 2003 with English Abstract.
2. EP 1 306 093 A1, published May 2, 2003.
3. WO 03/062440 A1, published July 31, 2003 was previously submitted on PTO/SB/08 dated July 28, 2006.
4. U.S. 2002/040052 A1, published April 4, 2002 to Ito et al.
5. JP 8-165237 A, published June 25, 1996 with English Abstract.
6. Feng Gui-Long et al., "Protection of methylflavonolamine against acute cerebral ischemia reperfusion injury in rats", Acta Pharmacologica Sinica, Vol. 16, No. 4, (1995), pp. 304-307.

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98
U.S. Appln. No.: 10/581,663

Attorney Docket No.: Q95272

7. M.A. Plotnikov et al., "Cerebroprotective Effects of Diquertin and Ascorbic Acid", Bulletin of Experimental Biology and Medicine, Vol. 130, No. 11, (2000), pp. 1080-1083.
8. Wang Leiyi et al., "Protective effect of Puerarin on acute cerebral ischemia in rats", Zhongguo Zhongyao Zazhi - China Journal of Chinese Materia Medica, Zhongguo Yaozuehui, Beijing, CN, Vol. 22, No. 12, December 1, 1997, pp. 752-754-765.
9. Shirvan Anat et al., "Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy", The Journal of Biological Chemistry, Vol. 277, No. 51, December 20, 2002, pp. 49799-49807 was previously submitted on PTO/SB/08 dated July 28, 2008.
10. Solomon Arieh S. et al., "Up-regulation of semaphorin expression in retina of glaucomatous rabbits", Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 241, No. 8, August 1, 2003, pp. 673-681 was previously submitted on PTO/SB/08 dated July 28, 2008.
11. K. Kumagai et al., "Xanthofulvin, a novel semaphoring inhibitor produced by a strain of Penicillium", Journal of Antibiotics, Japan Antibiotics Research Association, Vol. 56, No. 7, July 1, 2003, pp. 610-616.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant encloses herewith a copy of a corresponding Supplementary European Search Report citing references 1, 2, 4, 5, 6, 7, 8 and 11 indicating the degree of relevance found by the foreign patent office.

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98
U.S. Appln. No.: 10/581,663

Attorney Docket No.: Q95272

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


John T. Callahan
John T. Callahan
Registration No. 32,607

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: September 26, 2008